| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10912181 | Lung Cancer | 2005 | 11 Pages |
Abstract
Patients administered second-line chemotherapy had significantly longer survival than patients administered best supportive care. However, this difference can be explained by more negative prognostic factors in the best supportive care group. No survival difference between EP and CEV crossover chemotherapy was found. Multivariate analysis revealed PS at time of relapse as the only independent predictor of survival in the crossover recurrent SCLC group.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Stein Sundstrøm, Roy M. Bremnes, Stein Kaasa, Ulf Aasebø, Steinar Aamdal, For the Norwegian Lung Cancer Study Group For the Norwegian Lung Cancer Study Group,